Public Employees Retirement System of Ohio decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 895,648 shares of the biopharmaceutical company’s stock after selling 38,188 shares during the quarter. Public Employees Retirement System of Ohio owned approximately 0.07% of Gilead Sciences worth $63,394,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Keel Point LLC boosted its position in Gilead Sciences by 0.4% during the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 12 shares during the last quarter. West Oak Capital LLC boosted its position in Gilead Sciences by 0.7% during the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 32 shares during the last quarter. First Heartland Consultants Inc. boosted its position in Gilead Sciences by 0.4% during the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after acquiring an additional 39 shares during the last quarter. Princeton Portfolio Strategies Group LLC boosted its position in Gilead Sciences by 0.4% during the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after acquiring an additional 41 shares during the last quarter. Finally, Arrow Financial Corp raised its holdings in shares of Gilead Sciences by 0.3% during the second quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock valued at $1,258,000 after purchasing an additional 45 shares during the period. 76.23% of the stock is currently owned by institutional investors.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at approximately $5,788,299.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the completion of the sale, the insider now directly owns 3,070,099 shares of the company’s stock, valued at $230,196,023.02. The disclosure for this sale can be found here. Insiders sold a total of 494,999 shares of company stock valued at $37,404,139 over the last ninety days. 1.30% of the stock is currently owned by insiders.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $76.09 on Wednesday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The firm has a market cap of $96,951.29, a PE ratio of 7.75, a P/E/G ratio of -1.24 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same period in the prior year, the firm posted $2.75 EPS. The firm’s quarterly revenue was down 13.2% compared to the same quarter last year. analysts expect that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.73%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is 23.69%.

Several equities analysts have recently weighed in on the stock. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 7th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, September 11th. Vetr lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective on the stock. in a report on Monday, September 4th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $83.00 price objective (up previously from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $85.11.

ILLEGAL ACTIVITY NOTICE: “Public Employees Retirement System of Ohio Has $63.39 Million Position in Gilead Sciences, Inc. (GILD)” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.watchlistnews.com/public-employees-retirement-system-of-ohio-has-63-39-million-position-in-gilead-sciences-inc-gild/1760567.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.